Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

ImmunityBio, Inc.

NASDAQ: IBRX · Life Sciences · 6 alerts · CIK 1326110

Share price
$5.98Close, Nov 16
Market cap
$6.36B
Shares outstanding
1.06BLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All ImmunityBio, Inc. filings on SEC EDGAR ↗

7:53 AM ET 10-Q
Financial Results

ImmunityBio Q3 2026 Results: Net Loss of $185M, Loss Widens

ImmunityBio reported total assets of $609.4 million as of September 30, 2026, an increase from $501.9 million at year-end 2025, driven primarily by a rise in marketable securities. The company maintains a significant stockholders' deficit and continues to operate as a large accelerated filer following the commercial launch of its approved product, ANKTIVA.

Key figure
Net loss $185M
7:40 AM ET 8-K
Financial Results

ImmunityBio Financial Results

ImmunityBio reported Q3 2026 net product revenue of $48.7 million, a 53% increase year-over-year, driven by the adoption of ANKTIVA in the U.S. The company also highlighted a recent FDA label expansion for ANKTIVA and positive topline results from its QUILT-2.005 trial in BCG-naïve bladder cancer patients.

Term
Q3 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.